Sex and APOE Genotype Precision Therapeutic Targets Discovery for Alzheimer’s Disease

Case ID:

This technology encompasses a formulation for patient subgroup-specific supplement for the treatment and therapy of Alzheimer's and other neurodegenerative diseases. These formulations can range in delivery method (food, drink, pill) and can be specific to patient subgroups.

Alzheimer’s disease is a progressive, neurodegenerative disorder with few effective therapies and no cures. Additionally, cases and prevalence of Alzheimer’s disease are only projected to rise in the coming years. One of the challenging parts of Alzheimer’s disease is that it impacts different patients from different subgroups (age, gender, genetics) differently.

There are several drugs on the market that are effective in treating dementia related to Alzheimer’s disease, but none of them are curative, nor particularly specific to any patient subgroups. This technology is purposed to be patient subgroup-specific products to best help patients control their neurodegeneration.


  • Food or diets with patient subgroup-specific formulations
  • Supplement pills with patient subgroup-specific formulations


  • Patient subgroup-specific
  • Potential over-the-counter or pharmaceutical application
Patent Information:
Contact For More Information:
Mitch Graffeo
Sr. Licensing Manager - COM-T
The University of Arizona
Lead Inventor(s):
Rui Chang
Roberta Brinton
Rima Kaddurah-Daouk